RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

March 29 (UPI) --Rapper Playboi Carti's I Am Music is the No. 1 album in the United States this week. Coming in at No. 2 on the Billboard 200 chart dated Saturday is Lady Gaga's Mayhem, followed ...

The Official UK Singles Chart reflects the UK’s biggest songs of the week, based on audio and video streams, downloads, CDs and vinyl, compiled by the Official Charts Company. The UK Top 40 is ...

The Official UK Singles Chart reflects the UK’s biggest songs of the week, based on audio and video streams, downloads, CDs and vinyl, compiled by the Official Charts Company. The UK Top 40 is ...

Here below you have a complete description of its most interesting features and benefits so you can make the most of it. The majority of other information websites display prices of a single ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

TME UNI Chart, provided by Tencent Music Entertainment Group, ranks the top songs within China based on streaming and sales activity from seven major platforms (QQ Music, Kugou Music, Kuwo Music ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Bad Bunny Last week Weeks at no. 1 Weeks on chart Rimas Week of March 29, 2025 click to see more Rimas Josa ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...